A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Title A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Contact JJ

Principal Investigator Saby George, MD

Study Number 225212

Phase3

Summary To compare the clinical benefit, as measured by the duration of OS, provided by BMS-936558 vs everolimus in subjects with advanced or metastatic renal cell carcinoma who have received prior anti-angiogenic therapy.

Eligibility Please see ClinicalTrials.gov link.

For more information about the clinical study go to Clinicaltrial.Gov